Vanda Pharmaceuticals announced that its Phase III clinical trial of VQW-765, aimed at treating acute social anxiety, did not meet its primary or key secondary endpoints. The study involved 546 adults and tested the drug's effect during a stress-inducing public speaking test but found no significant difference from placebo. Despite earlier promising Phase II results, the Phase III findings were negative, leading Vanda to pause the development program pending further data analysis. VQW-765 is a novel drug targeting the alpha 7 nicotinic acetylcholine receptor, with potential psychiatric applications but no current FDA approval for performance anxiety treatment.
Vanda Pharmaceuticals' update on its VQW-765 clinical development program is provided here with related market data. For readers following the health sector, 90 of 150 priced US health stocks on Pluang rose while 60 fell. Notable movers include CGC at USD 0.72 with a 5.60% decline and 98% sell order activity, CLPT at USD 9.30 down 5.20%, and WGS at USD 68.25 up 5.06% with 100% buy order activity. Data is as of Oct 15, 2026 03:02 WIB.
The Law Offices of Frank R. Cruz is investigating Alignment Healthcare following a whistleblower lawsuit claiming the company misclassified $8-10 million in expenses to inflate its adjusted EBITDA and stock price. This alleged accounting manipulation...
Lakefront Biotherapeutics has completed the sale of its preclinical CAR-T cell therapy programs to Belgium-based Armed Cell Therapeutics. The deal includes an upfront payment of €8 million, potential milestone payments up to $230 million, and a low s...
PNC Financial Services Group is set to report its Q3 2026 earnings with analysts forecasting earnings of around $4.91 per share and revenue near $6.61 billion, reflecting solid growth. The bank anticipates a 3%–3.5% rise in net interest income and 1%...
Leonardo DRS secured a 10-year prime contract under NASA's SEWP VI program, enabling federal agencies to quickly procure its defense products and services until 2036. This contract extends DRS's role as a SEWP prime contractor, supporting key militar...
Honey Badger Silver announced promising assay results from its first exploration program at the Yava Project in Nunavut, revealing high-grade silver, copper, gold, zinc, and lead samples. This marks the first systematic work at Yava in nearly two dec...
